Johnson & Johnson

Feasibility assessment of electronic health records data in relation to the disease area Geographic Atrophy (GA)

Late-stage macular degeneration, also known as geographic atrophy (GA), accounts for about one quarter of legal blindness in the UK. Patients with GA lose central vision due to retinal lesions expanding over several years, with older patients most at risk. We will quantify long-term health and quality of life impacts for GA patients, as well as healthcare resource use and treatment costs. The primary clinical outcome is the proportion of patients with visual impairment, with secondary outcomes including changes in visual acuity, falls, accidents, mortality, depression, hospitalisations, and social services use. West Midlands SDE datasets will help evaluate the need and benefits of innovative therapeutics and demonstrate cost-effectiveness through potential reduced costs and resource use in the NHS. Our results will support decision-making and resource allocation for GA patients in West Midlands SDE. Initially, the study will evaluate patient counts, disease measures, outcomes, and clinical characteristics to determine the feasibility of proceeding to a full study.

In order to estimate the positive impact of innovative treatments for GA to UK patients, we need to understand the burden of the disease to UK patients and the potential future impact on health outcomes a treatment may have as well as the existing current cost and resource impact to the NHS which could be alleviated in the future. This can also be informative to the NHS from a resource and cost consideration perspective as well as understanding the patient population more fully.

03/12/2024

SDE101

West Midlands SDE trusted research environment

Not yet published.